Article
ERK1/2 Inhibition Alleviates Noise-Induced Hearing Loss While Tempering Down the Immune Response
2023-10-20
Abstract excerpt
Noise-induced hearing loss (NIHL) is a major cause of hearing impairment, yet no FDA-approved drugs exist to prevent it. Targeting the mitogen activated protein kinase (MAPK) cellular pathway has emerged as a promising approach to attenuate NIHL. Tizaterkib is an orally bioavailable, highly specific ERK1/2 inhibitor, currently in Phase-1 anticancer clinical trials. Here, we tested tizaterkib’s efficacy against per...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f1dccf81-cb05-5e5d-879a-64924659ab5b
- DOI
- 10.1101/2023.10.18.563007
